Tevogen Bio (TVGN) Stock Price, News & Analysis

Company Overview

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections. Its research and development efforts seek to harness both non-engineered and engineered NK cells, including chimeric antigen receptor (CAR) NK constructs, to address a broad range of diseases. The company’s technology platform is protected by patents covering manufacturing processes and product compositions.

Founded in 2013 by a team of immunotherapy experts, Tevogen Bio maintains research facilities in the United States, Israel and Denmark. Under the leadership of co-founder and Chief Executive Officer Khurshid Guru, the company has progressed from early-stage discovery to clinical development. It is actively expanding its manufacturing capabilities to support late-stage trials and future commercialization efforts.

Tevogen Bio collaborates with academic institutions and drug development partners to accelerate its pipeline. The company engages with regulatory authorities in North America and Europe as it advances clinical programs and prepares for potential market entry. By focusing on the innate immune system and personalized therapeutic approaches, Tevogen Bio aims to address unmet medical needs in oncology and viral disease treatment.

Key Stats

• Today's Range: $8.18 to $9.92
• 50-Day Range: $4.29 to $11.56
• 52-Week Range: $4.14 to $75.50
• Volume: 15,172 shs
• Average Volume: 37,822 shs
• Market Capitalization: $37.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Reduce

Tevogen Bio Stock Analysis - MarketRank™

Tevogen Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 740th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Tevogen Bio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tevogen Bio has a consensus price target of $100.00, representing about 1,003.8% upside from its current price of $9.06.

Amount of Analyst Coverage

Tevogen Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tevogen Bio is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tevogen Bio is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.73% of the float of Tevogen Bio has been sold short.

Short Interest Ratio / Days to Cover

Tevogen Bio has a short interest ratio ("days to cover") of 3.96, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tevogen Bio has recently increased by 11.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tevogen Bio does not currently pay a dividend.

Dividend Growth

Tevogen Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.87

News Sentiment

Tevogen Bio has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Tevogen Bio this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TVGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Tevogen Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tevogen Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,635.00 in company stock.

Percentage Held by Insiders

70.51% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Tevogen Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVGN
• Previous Symbol: NASDAQ:TVGN
• CIK: 1860871
• Web: www.semperparatusspac.com
• Phone: 913-579-4170
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tevogen Bio: $100.00
• High Price Target: $100.00
• Low Price Target: $100.00
• Potential Upside/Downside: +1,003.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -472.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.29
• Quick Ratio: 0.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($211.84) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 4,160,000
• Free Float: 1,228,000
• Market Cap: $37.69 million
• Optionable: N/A
• Beta: 0.14